Barbara obtained her MD from McGill University in Montreal, Canada, and completed general internal medicine with specialty in Endocrinology and Metabolism at the University of Toronto. Following this, she did basic science research at Beth Israel Deaconess Hospital in Boston and clinical work at Northwestern Memorial Hospital in Chicago while continuing basic science research in obesity. Barbara joined pharmaceutical industry in 1998 as an Associate Director of Postmarketing Safety at Searle, and then joined Abbott in 2000. While at Abbott/AbbVie, she started in Pharmacovigilance in Postmarketing safety, then moved to clinical development where she managed HIV clinical studies, was Abbott/AbbVie’s representative for the HAART Oversight Committee, and was part of the HCV clinical development team. More recently, Barbara was the Product Safety Lead taking AbbVie’s direct acting antiviral regimen from Phase 1 through marketing authorization. Barbara has published throughout her career including clinical and basic science research and during pharmaceutical drug development. Currently Barbara is a Senior Medical Director in the Benefit Risk Management group at AbbVie.